Scientists test new Drug's safety alongside standard IPF therapies
Knowledge-focused
Not yet recruiting
This early-stage study aims to understand how a potential new drug for Idiopathic Pulmonary Fibrosis (IPF), called ENV-101, interacts with two standard medications (nintedanib and pirfenidone). It will enroll 57 healthy participants to measure how the body absorbs and processes t…
Phase: PHASE1 • Sponsor: Endeavor Biomedicines, Inc. • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC